@article{10.25259/IJSA_8_2023, title = {Ligelizumab: A novel molecule in the management of chronic spontaneous urticaria}, author = {Datta, Shreya and Chakraborty, Disha and De, Abhishek}, abstract = { The next-generation high affinity monoclonal immunoglobulin E (IgE) inhibitor Ligelizumab is being tested in clinical studies to treat chronic spontaneous urticaria (CSU). In 2020, the US Food and Drug Administration (FDA) designated Ligelizumab (QGE031) as a breakthrough therapy for patients with chronic idiopathic urticaria; however, FDA clearance has not yet been granted, despite the phase 3 trial’s completion. Recent clinical investigations have shown that it has a considerable affinity for the high-affinity IgE receptor (FcRI) on the surface of immune cells, which is quite beneficial in the management of the distressing symptoms of CSU. Studies have been done comparing Ligelizumab to Omalizumab, the current standard of care for treating CSU that is refractory. While omalizumab is more effective than Ligelizumab at inhibiting IgE: CD23 interactions, Ligelizumab exhibits stronger inhibition of IgE binding to FcRI, basophil activation, IgE synthesis by B cells, and passive systemic anaphylaxis. To learn about this molecule’s extended characteristics, long-term efficacy and safety, and potential uses in other dermatological disorders, more clinical data is needed. }, volume = 2, journal = {Indian Journal of Skin Allergy}, issn = {2834-0671}, issn = {2831-7947}, url = {https://doi.org/10.25259/IJSA_8_2023}, doi = {10.25259/IJSA_8_2023} }